Patents Assigned to University of Basel
  • Publication number: 20190211020
    Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), neurodegenerative diseases (e.g., Alzheimer's disease), metabolic diseases (e.g. diabetes), neurodevelopmental disorders (e.g. autism), or psychiatric disorders (e.g. schizophrenia or anxiety)) as well as methods of treating these diseases.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 11, 2019
    Applicants: Agency for Science, Technology and Research, University of Basel
    Inventors: Kassoum Nacro, Stephane Baudouin, Peter Scheiffele
  • Patent number: 9746493
    Abstract: The present invention relates to sample holders for holding a sample, particularly for an atomic force microscope. Such a sample holder comprising a sample dish (1) comprising a bottom (2), and an opening (3) arranged in said bottom (2) for receiving and holding the sample (15). Furthermore the present invention relates to a sample holder system and to a method for transferring an e.g. biological sample (15) from a biopsy tool (18) to a sample holder.
    Type: Grant
    Filed: July 5, 2014
    Date of Patent: August 29, 2017
    Assignee: University of Basel
    Inventors: Marko Loparic, Pascal Alexander Oehler
  • Patent number: 9028820
    Abstract: The invention relates to monoclonal antibodies directed to a particular part of tropomyosin-related kinase B receptor (TrkB) and hybridoma cell lines producing these. Fragments of these antibodies, in particular fragments representing complementarity determining regions (CDRs), and proteins comprising these, are useful in a method of treating cancer, pain, anorexia, anorexia nervosa and/or cachexia.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: May 12, 2015
    Assignee: University of Basel
    Inventors: Karl Hofbauer, Jean-Christophe Peter
  • Patent number: 8993244
    Abstract: The invention relates to an assay for the identification of a compound having immunosuppressant activity, wherein a candidate compound is analyzed whether it blocks the Ca2+ flux in coronin 1 expressing cells and/or in coronin 1 negative cells. A candidate compound is identified as having immunosuppressant activity if it blocks the Ca2+ flux specifically in coronin 1 expressing cells. Further described are upstream assays wherein the impact of a candidate compound on coronin 1 trimerization is measured, and downstream assays wherein the impact of a candidate compound on diacyl glycerol (DAG) generation, phosphatidylinositol-4,5-biphosphate (PIP2) levels and/or inositol-1,4,5-triphosphate (InsP3) generation or on nuclear factor of activated T cells (NFAT) nuclear localization is determined.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: March 31, 2015
    Assignee: University of Basel
    Inventors: Jean Pieters, Rajesh Jayac Han Dran, Philipp Mueller
  • Publication number: 20150038506
    Abstract: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), neurodegenerative diseases (e.g., Alzheimer's disease), metabolic diseases (e.g. diabetes), neurodevelopmental disorders (e.g. autism), or psychiatric disorders (e.g. schizophrenia or anxiety)) as well as methods of treating these diseases.
    Type: Application
    Filed: October 17, 2014
    Publication date: February 5, 2015
    Applicants: Agency for Science, Technology and Research, University of Basel
    Inventors: Kassoum Nacro, Stephane Baudouin, Peter Scheiffele
  • Patent number: 8921361
    Abstract: The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compounds^ Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. •Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: December 30, 2014
    Assignee: University of Basel
    Inventors: Vladimir Cmiljanovic, Natasa Cmiljanovic, Bernd Giese, Matthias Wymann
  • Patent number: 8728438
    Abstract: The invention relates to the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation using coronin 1 and modulators of coronin 1. Particular modulators of coronin 1 are compounds which inhibit the production of coronin 1 or the formation of active coronin 1 from a coronin 1 precursor, partly or entirely inactivate coronin 1, inhibit concentration of coronin 1 at the site of T cell activation, or inhibit the coronin 1 mediated signaling pathway downstream of the T cell receptor. Examples of such modulators are antibody or antibody fragments, coronin 1 peptide fragments or corresponding phosphopeptides, or anti-sense oligonucleotides, e.g. siRNA or shRNA.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: May 20, 2014
    Assignee: University of Basel
    Inventors: Jean Pieters, Rajesh Jayachandran
  • Publication number: 20140112928
    Abstract: The invention relates to monoclonal antibodies directed to a particular part of tropomyosin-related kinase B receptor (TrkB) and hybridoma cell lines producing these. Fragments of these antibodies, in particular fragments representing complementarity determining regions (CDRs), and proteins comprising these, are useful in a method of treating cancer, pain, anorexia, anorexia nervosa and/or cachexia.
    Type: Application
    Filed: May 18, 2012
    Publication date: April 24, 2014
    Applicant: UNIVERSITY OF BASEL
    Inventors: Karl Hofbauer, Jean-Christophe Peter
  • Publication number: 20130336966
    Abstract: The invention relates to the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation using coronin 1 and modulators of coronin 1. Particular modulators of coronin 1 are compounds which inhibit the production of coronin 1 or the formation of active coronin 1 from a coronin 1 precursor, partly or entirely inactivate coronin 1, inhibit concentration of coronin 1 at the site of T cell activation, or inhibit the coronin 1 mediated signaling pathway downstream of the T cell receptor. Examples of such modulators are antibody or antibody fragments, coronin 1 peptide fragments or corresponding phosphopeptides, or anti-sense oligonucleotides, e.g. siRNA or shRNA.
    Type: Application
    Filed: July 29, 2013
    Publication date: December 19, 2013
    Applicant: UNIVERSITY OF BASEL
    Inventors: Jean PIETERS, Rajesh JAYACHANDRAN
  • Patent number: 8553973
    Abstract: Methods and/or systems for modeling 3-dimensional objects (for example, human faces). In certain example embodiments, methods and/or systems usable for computer animation or static manipulation or modification of modeled images (e.g., faces), image processing, or for facial (or other object) recognition methods and/or systems.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: October 8, 2013
    Assignee: University of Basel
    Inventors: Reinhard Tobias Knothe, Thomas Vetter
  • Patent number: 8518372
    Abstract: The invention relates to the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation using coronin 1 and modulators of coronin 1. Particular modulators of coronin 1 are compounds which inhibit the production of coronin 1 or the formation of active coronin 1 from a coronin 1 precursor, partly or entirely inactivate coronin 1, inhibit concentration of coronin 1 at the site of T cell activation, or inhibit the coronin 1 mediated signaling pathway downstream of the T cell receptor. Examples of such modulators are antibody or antibody fragments, coronin 1 peptide fragments or corresponding phosphopeptides, or anti-sense oligonucleotides, e.g. siRNA or shRNA.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: August 27, 2013
    Assignee: University of Basel
    Inventors: Jean Pieters, Rajesh Jayachandran
  • Publication number: 20130079467
    Abstract: A synthetic material (22), a sensor comprising the synthetic material (22) and a method for making the synthetic material (22) and the sensor, respectively, as well as the use of this synthetic material (22) as a construction material and/or a high performing material, especially in the areas of aeronautics, aerospace, automotive, wind turbines and sporting goods. The synthetic material (22) comprising at least two phases (2, 9) and an optical detectable component (26, 16), wherein at least one of said phases is a solid phase building a matrix (20) of the synthetic material (22), and wherein the optical detectable component (26, 16) changes its optical properties (symbol 5, 7) when its intact structure is perturbed (8/26?), said optical detectable component (26, 16) is bond to both phases (2, 9) of the synthetic material (22).
    Type: Application
    Filed: May 27, 2011
    Publication date: March 28, 2013
    Applicant: UNIVERSITY OF BASEL
    Inventors: Nico Bruns, Samuel Loercher
  • Publication number: 20130040912
    Abstract: The invention relates to compounds of formula (I) R1 is methyl, n-hexyl, aminoethyl, methylaminoethyl, ethylaminoethyl, dimethylaminoethyl, acryloylaminoethyl, methacryloylaminoethyl, methoxyethyl, ethoxyethyl, d-C4-alkyl-sulfonyl, acryloyl, or methacryloyl; or R1 is aminoethyl, acryloyl or acryloylaminoethyl carrying a linker and a tag, and R2 and R3, independently of each other, are hydrogen or CrC4-alkyl, or R2 and R3 together form a methylene or an ethylene bridge; and tautomers, solvates and pharmaceutically acceptable salts thereof. These compounds are effective in preventing or treating a disease or disorder modulated by PI3 kinases and/or mTOR, in particular treating a hyperproliferative disorder.
    Type: Application
    Filed: April 27, 2011
    Publication date: February 14, 2013
    Applicant: UNIVERSITY OF BASEL
    Inventors: Vladimir Cmiljanovic, Natasa Cmiljanovic, Bernd Giese, Matthias Wymann
  • Publication number: 20120107938
    Abstract: The present invention concerns methods and kits for the direct, targeted engineering of conditional alleles in rodent embryonic stem cells in which the conditional allele is replaced with a DNA of interest without first introducing heterotypic recombination sites, thus providing high efficiency targeted exchange of genetic material.
    Type: Application
    Filed: June 28, 2010
    Publication date: May 3, 2012
    Applicant: UNIVERSITY OF BASEL
    Inventors: Javier Lopez-Rios, Rolf Zeller, Marco Osterrwalder
  • Patent number: 8084258
    Abstract: The present invention is directed to methods for altering the fate of a cell, tissue or organ type by altering Notch pathway function in the cell. The invention is further directed to methods for altering the fate of a cell, tissue or organ type by simultaneously changing the activation state of the Notch pathway and one or more cell fate control gene pathways. The invention can be utilized for cells of any differentiation state. The resulting cells may be expanded and used in cell replacement therapy to repopulate lost cell populations and help in the regeneration of diseased and/or injured tissues. The resulting cell populations can also be made recombinant and used for gene therapy or as tissue/organ models for research. The invention is directed to methods for of treating macular degeneration comprising altering Notch pathway function in retinal pigment epithelium cells or retinal neuroepithelium or both tissues.
    Type: Grant
    Filed: January 5, 2004
    Date of Patent: December 27, 2011
    Assignees: University of Basel, Yale University
    Inventors: Walter Gehring, Spyridon Artavanis-Tsakonas
  • Publication number: 20110275762
    Abstract: The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compounds? Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. •Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: November 10, 2009
    Publication date: November 10, 2011
    Applicant: UNIVERSITY OF BASEL
    Inventors: Vladimir Cmiljanovic, Natasa Cmiljanovic, Bernd Giese, Matthias Wymann
  • Patent number: 8008446
    Abstract: Disclosed are biological markers for obesity and methods for diagnosing and treating obesity and related conditions by detecting and modulating the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor. Also disclosed are methods for discovering new therapeutics which modulate the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor, in particular which prevent the binding of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: August 30, 2011
    Assignee: University of Basel
    Inventors: Karl Hofbauer, Jean-Christophe Peter
  • Publication number: 20110123994
    Abstract: The invention relates to an assay for the identification of a compound having immunosuppressant activity, wherein a candidate compound is analyzed whether it blocks the Ca2+ flux in coronin 1 expressing cells and/or in coronin 1 negative cells. A candidate compound is identified as having immunosuppressant activity if it blocks the Ca2+ flux specifically in coronin 1 expressing cells. Further described are upstream assays wherein the impact of a candidate compound on coronin 1 trimerization is measured, and downstream assays wherein the impact of a candidate compound on diacyl glycerol (DAG) generation, phosphatidylinositol-4,5-biphosphate (PIP2) levels and/or inositol-1,4,5-triphosphate (InsP3) generation or on nuclear factor of activated T cells (NFAT) nuclear localization is determined.
    Type: Application
    Filed: March 12, 2009
    Publication date: May 26, 2011
    Applicant: UNIVERSITY OF BASEL
    Inventors: Jean Pieters, Rajesh Jayac Han Dran, Philipp Mueller
  • Publication number: 20110075916
    Abstract: Methods and/or systems for modeling 3-dimensional objects (for example, human faces). In certain example embodiments, methods and/or systems usable for computer animation or static manipulation or modification of modeled images (e.g., faces), image processing, or for facial (or other object) recognition methods and/or systems.
    Type: Application
    Filed: July 7, 2010
    Publication date: March 31, 2011
    Applicant: UNIVERSITY OF BASEL
    Inventors: Reinhard Tobias KNOTHE, Thomas VETTER
  • Publication number: 20100239535
    Abstract: The invention is directed to a method for producing precursor cells expressing a target gene, for example VEGF, at desired levels comprising stably transducing precursor cells with the target gene linked to a cell-surface marker gene, for example truncated CD8/CD8a, via an IRES sequence accommodating translation of the target and the marker genes from the same mRNA, then correlating an expression level of the target gene with that of the cell-surface marker gene, selecting a reference clone of cultured precursor cells expressing the target gene at the desired threshold, and isolating precursor cells having the same or similar level of expression of the target gene than the reference clone.
    Type: Application
    Filed: May 16, 2007
    Publication date: September 23, 2010
    Applicant: UNIVERSITY OF BASEL
    Inventors: Andrea Banfi, Heidi Misteli